Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
Authors
Keywords
-
Journal
MOLECULAR PSYCHIATRY
Volume 17, Issue 12, Pages 1206-1227
Publisher
Springer Nature
Online
2012-05-15
DOI
10.1038/mp.2012.47
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dosing Atypical Antipsychotics
- (2016) Andrew Cutler et al. CNS SPECTRUMS
- Multifunctional Drugs: A Novel Concept for Psychopharmacology.
- (2016) Stephen M. Stahl CNS SPECTRUMS
- N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
- (2014) Olivia Dean et al. JOURNAL OF PSYCHIATRY & NEUROSCIENCE
- Long-term Antipsychotic Treatment and Brain Volumes
- (2011) Beng-Choon Ho et al. ARCHIVES OF GENERAL PSYCHIATRY
- Emerging drugs for schizophrenia
- (2011) Falko Biedermann et al. EXPERT OPINION ON EMERGING DRUGS
- Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment
- (2011) David J. G. Watson et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST)
- (2011) Jan Volavka et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Double-Blind, Randomized, Placebo-Controlled Study of the Dopamine D3 Receptor Antagonist ABT-925 in Patients With Acute Schizophrenia
- (2011) Laura Redden et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia
- (2011) Bruce J. Kinon et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial
- (2011) Joo-Cheol Shim et al. NEUROPSYCHOPHARMACOLOGY
- Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia
- (2011) Cort A. Pedersen et al. SCHIZOPHRENIA RESEARCH
- Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial
- (2011) Douglas L. Boggs et al. SCHIZOPHRENIA RESEARCH
- Therapeutic Potential of 5-HT2CReceptor Ligands
- (2011) Nanna H. Jensen et al. TheScientificWorldJOURNAL
- Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders
- (2010) G. Paul Amminger et al. ARCHIVES OF GENERAL PSYCHIATRY
- Prospects for Minocycline Neuroprotection
- (2010) Jennifer M. Plane et al. ARCHIVES OF NEUROLOGY
- Adjunctive Intranasal Oxytocin Reduces Symptoms in Schizophrenia Patients
- (2010) David Feifel et al. BIOLOGICAL PSYCHIATRY
- A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia
- (2010) Robert W. Buchanan et al. BIOLOGICAL PSYCHIATRY
- Effects of an Alpha 7-Nicotinic Agonist on Default Network Activity in Schizophrenia
- (2010) Jason R. Tregellas et al. BIOLOGICAL PSYCHIATRY
- Challenges for and current status of research into positive modulators of AMPA receptors
- (2010) Simon E Ward et al. BRITISH JOURNAL OF PHARMACOLOGY
- Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis
- (2010) Guochuan Tsai et al. CURRENT PHARMACEUTICAL DESIGN
- 5-HT6 Receptor Antagonists as Potential Therapeutics for Cognitive Impairment
- (2010) Gerard Rosse et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Metabotropic Glutamate Receptors as Therapeutic Targets for Cognitive Disorders
- (2010) A. Gravius et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone
- (2010) M.A. Crocq et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Recent advances in histamine H3receptor antagonists/inverse agonists
- (2010) Dorota Łażewska et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia
- (2010) Deanna L. Kelly et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
- (2010) B. Kiss et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Review: Suicide and schizophrenia: a systematic review of rates and risk factors
- (2010) Kahyee Hor et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia
- (2010) T Wüstenberg et al. MOLECULAR PSYCHIATRY
- Rethinking schizophrenia
- (2010) Thomas R. Insel NATURE
- Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies
- (2010) Terry E Goldberg et al. NEUROPSYCHOPHARMACOLOGY
- The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action
- (2010) Erik H.F. Wong et al. PHARMACOLOGY & THERAPEUTICS
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
- (2010) Christine Rummel-Kluge et al. SCHIZOPHRENIA RESEARCH
- Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment
- (2010) Norbert Müller et al. SCHIZOPHRENIA RESEARCH
- Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia
- (2010) Jean-Pierre Lindenmayer et al. SCHIZOPHRENIA RESEARCH
- A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
- (2010) Akihiro Shiina et al. Annals of General Psychiatry
- Omega-3 fatty acids: potential role in the management of early Alzheimer’s disease
- (2010) Greg Jicha Clinical Interventions in Aging
- Secretin Effects on Cerebellar-Dependent Motor Learning in Schizophrenia
- (2009) Amanda R. Bolbecker et al. AMERICAN JOURNAL OF PSYCHIATRY
- Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)
- (2009) Michael Davidson et al. AMERICAN JOURNAL OF PSYCHIATRY
- TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia
- (2009) T.A. Hauser et al. BIOCHEMICAL PHARMACOLOGY
- Intranasal Oxytocin Improves Emotion Recognition for Youth with Autism Spectrum Disorders
- (2009) Adam J. Guastella et al. BIOLOGICAL PSYCHIATRY
- Blonanserin
- (2009) Emma D. Deeks et al. CNS DRUGS
- Antipsychotics in the early stage of development
- (2009) Falko Biedermann et al. CURRENT OPINION IN PSYCHIATRY
- Therapeutic Utility of NK3 Receptor Antagonists for the Treatment of Schizophrenia
- (2009) Lee Dawson et al. CURRENT PHARMACEUTICAL DESIGN
- Drugs in development for the treatment of schizophrenia
- (2009) Robin Emsley EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Patented PDE10A inhibitors: novel compounds since 2007
- (2009) Jan Kehler et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Effect of second-generation antipsychotics on cognition: current issues and future challenges
- (2009) S Kristian Hill et al. Expert Review of Neurotherapeutics
- A randomized, double-blind, placebo-controlled comparison study of sarcosine ( N-methylglycine) and d-serine add-on treatment for schizophrenia
- (2009) Hsien-Yuan Lane et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats
- (2009) Vera Bubenikova-Valesova et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia
- (2009) Vidhi Singh et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Adjunctive α2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission
- (2009) Monica M. Marcus et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Intervention in Individuals at Ultra-High Risk for Psychosis
- (2009) Patrick D. McGorry et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
- (2009) Yechiel Levkovitz et al. JOURNAL OF CLINICAL PSYCHIATRY
- Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia
- (2009) S. M. Grauer et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
- (2009) Christine E Marx et al. NEUROPSYCHOPHARMACOLOGY
- Functional Magnetic Resonance Imaging of Effects of a Nicotinic Agonist in Schizophrenia
- (2009) Jason R Tregellas et al. NEUROPSYCHOPHARMACOLOGY
- Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death
- (2009) Wayne A. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Food Intake-independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism
- (2009) Daniela Cota et al. Obesity
- Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo
- (2009) Atheir I. Abbas et al. PSYCHOPHARMACOLOGY
- Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder
- (2009) Robert C. Smith et al. SCHIZOPHRENIA RESEARCH
- Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia
- (2008) David A. Lewis et al. AMERICAN JOURNAL OF PSYCHIATRY
- Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
- (2008) Robert Freedman et al. AMERICAN JOURNAL OF PSYCHIATRY
- Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
- (2008) Anantha Shekhar et al. AMERICAN JOURNAL OF PSYCHIATRY
- Estrogen in Severe Mental Illness
- (2008) Jayashri Kulkarni et al. ARCHIVES OF GENERAL PSYCHIATRY
- Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the α7 nicotinic acetylcholine receptor: In vitro and in vivo activity
- (2008) Brad A. Acker et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The histamine H3receptor: an attractive target for the treatment of cognitive disorders
- (2008) T A Esbenshade et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat
- (2008) B Marcos et al. BRITISH JOURNAL OF PHARMACOLOGY
- Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia
- (2008) Jeffrey W. Swanson et al. BRITISH JOURNAL OF PSYCHIATRY
- The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia
- (2008) Robert R. Conley et al. CLINICAL NEUROPHARMACOLOGY
- Emerging drugs for schizophrenia
- (2008) Ofer Agid et al. EXPERT OPINION ON EMERGING DRUGS
- Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders
- (2008) Atheir Abbas et al. EXPERT OPINION ON PHARMACOTHERAPY
- Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS)
- (2008) Nicole Maninger et al. FRONTIERS IN NEUROENDOCRINOLOGY
- Heterogeneity of violence in schizophrenia and implications for long-term treatment
- (2008) J. Volavka et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- ADX47273 [S-(4-Fluoro-phenyl)- -methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities
- (2008) F. Liu et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
- (2008) René S Kahn et al. LANCET
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
- (2008) Stefan Leucht et al. LANCET
- Schizophrenia: Moving Beyond Monoamine Antagonists
- (2008) P. J. Conn et al. MOLECULAR INTERVENTIONS
- Serotonergic approaches in the development of novel antipsychotics
- (2008) Caitlin A. Jones et al. NEUROPHARMACOLOGY
- An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function
- (2008) Kevin C.F. Fone NEUROPHARMACOLOGY
- Building a better antipsychotic: Receptor targets for the treatment of multiple symptom dimensions of schizophrenia
- (2008) Dennis H. Kim et al. Neurotherapeutics
- Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system
- (2008) Anna-Leena Sirén et al. Neurotherapeutics
- Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
- (2008) J. A. Lieberman et al. PHARMACOLOGICAL REVIEWS
- Antagonism of dopamine D2 receptor/ -arrestin 2 interaction is a common property of clinically effective antipsychotics
- (2008) B. Masri et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study
- (2008) Shahin Akhondzadeh et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Effect of R3487/MEM3454, a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats
- (2008) Amir H. Rezvani et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature
- (2008) J. M. Stone et al. SCHIZOPHRENIA BULLETIN
- Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia
- (2008) Kristi A. Sacco et al. SCHIZOPHRENIA RESEARCH
- High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia
- (2008) M DYER et al. SCHIZOPHRENIA RESEARCH
- World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia
- (2008) Rajiv Tandon et al. SCHIZOPHRENIA RESEARCH
- Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial
- (2008) Shahin Akhondzadeh et al. SCHIZOPHRENIA RESEARCH
- Cognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D3 > D2 Antagonist, S33138
- (2008) Mark J. Millan et al. THERAPIE
- A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory
- (2008) M KING et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Galantamine for the Treatment of Cognitive Impairments in People With Schizophrenia
- (2007) Robert W. Buchanan et al. AMERICAN JOURNAL OF PSYCHIATRY
- Cognitive dysfunction in neuropsychiatric disorders: Selected serotonin receptor subtypes as therapeutic targets
- (2007) Alvin V. Terry et al. BEHAVIOURAL BRAIN RESEARCH
- Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study
- (2007) Hsien-Yuan Lane et al. BIOLOGICAL PSYCHIATRY
- Effect of Chronic Antipsychotic Exposure on Astrocyte and Oligodendrocyte Numbers in Macaque Monkeys
- (2007) Glenn T. Konopaske et al. BIOLOGICAL PSYCHIATRY
- Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline
- (2007) Yuko Fujita et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started